psoriasis. Plaque psoriasis
Conditions
Interventions
Intervention 1: oral methotrexate 7.5 t0 15 mg per week for intervention group for 16 weeks, pioglitazone 30 mg per day orally for 16 weeks. Intervention 2: oral methotrexate 7.5 t0 15 mg per week fo
Treatment - Drugs
oral methotrexate 7.5 t0 15 mg per week for intervention group for 16 weeks, pioglitazone 30 mg per day orally for 16 weeks.
oral methotrexate 7.5 t0 15 mg per week for control group for 16 weeks.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: plaque type psoriasis; Indication for systemic therapy; Phototherapy contraindicated; No systemic therapy or phototherapy in last 6 months Exclusion criteria: congestive heart failure; renal disease ; hepatic or pulmonary disease; abnormal hepatic enzymes; diabetes; pregnancy or lactation; potential for childbearing; any other major systemic diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis area and severity index (PASI). Timepoint: at weeks 0, 6, 10, 16. Method of measurement: PASI meter.;Dermatology life quality index (DLQI). Timepoint: at weeks 0,6,10,16. Method of measurement: Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatic enzymes. Timepoint: at weeks 0, 1,2,4,6,10,16. Method of measurement: blood biochemistry.;Complete blood cells (CBC). Timepoint: at weeks 0,1,2,4,6,10,16. Method of measurement: automated analyzer (Automated blood count).;Lipid profile. Timepoint: at weeks, 0, 6,10, 16. Method of measurement: Lipid Blood Tests.;Bun and creatinine. Timepoint: at weeks 0,6,10,16. Method of measurement: blood biochemistry.;Urine analysis. Timepoint: at weeks 0,6,10,16. Method of measurement: Urine test strip. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoroush Daklan
Tehran University of Medical Sciences
Outcome results
None listed